1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65A2A85F80429869865257EA50026A16A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/enabling-marketing-insights-superior-competitiveness-through-faster-market-research-approvals?opendocument
18
19opendocument
2018.212.83.37
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Market Research, Analytics and Forecasting Process Excellence and Productivity Management

Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals

ID: PSM-323


Features:

41 Info Graphics

37 Data Graphics

500+ Metrics

38 Narratives

42 Best Practices


Pages: 113


Published: 2015


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Market research studies provide biopharmaceutical companies with strategic insights necessary to sustain in a rapidly changing marketplace. These studies are particularly vital for companies focused on specialty therapeutic areas and rare diseases, given the small target population and intensifying competition.

However, delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, companies must develop a tactical approach to expedite the market research approval process for quicker and meaningful insights.

Best Practices, LLC undertook a study to evaluate how biopharmaceutical companies involved in specialty therapeutic areas and rare diseases manage the market research approval process. The study provides insights and metrics around the management of roles and responsibilities, cycle times, honoraria requirements, non-conforming requests and vendors.

Watch the Report's Overview:


Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Technology; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbvie; actavis; Amgen; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; CSL Behring; Fresenius Kabi; Genentech; Grifols; Jazz Pharmaceuticals; Lilly; NeedleTech Products Inc.; Novartis; Novo Nordisk; Philips Healthcare; Roche; Sanofi; Teva Pharmaceutical Industries Ltd; UCB Pharma


Study Snapshot

This study engaged 22 executives from 21 leading pharmaceutical, biotech, and life sciences companies. Eleven companies responded on behalf of rare disease markets. 40% of companies participated in deep-dive interviews about the drivers of operational excellence. Three-fourths of respondents are directors or heads of market research.

Key Findings

Cycle Time Review Key Metric for Assessing MR Approval Process: Nearly three-quarters of participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. Study cost and recruiting failure rates are metrics used by 43% of the benchmark class.

    Best Practice Checklists: Employ best practices, checklists and rules for high performance. Begin with checklists in pinch points that are most problematic. Then extend to entire process and operations. Checklists help control processes.

Table of Contents

I. Executive Summary pgs. 3-7
Research Overview pg. 4

Participating Companies pg. 5

II. Key Findings & Insights pg. 8

III. Best Practices of High-Performing Companies pg. 16

IV. Managing Cycle Times & Fast Response pg. 36

V. Managing Roles & Responsibilities pg. 50

VI. Managing Honoraria Services pg. 57

VII. Managing Non-conforming Requests pg. 69

VIII. Approval Process Excellence pg. 72

IX. Best Practice Case Study: How One Company Evolved Fast & Efficient Approval Systems pg. 80

X. Lessons Learned & Pitfalls to Avoid pg. 93

XI. Field Interviews & Executive Verbatims pg. 98

XII. Path Forward Recommendations pg. 104

XIII. Benchmark Class Demographics pg. 108

XIV. About Best Practices, LLC pg. 112